Try a new search

Format these results:

Searched for:

person:hoganj02

in-biosketch:true

Total Results:

5


Strongyloides stercoralis infection in solid organ transplant recipients

Hogan, John I; Mehta, Sapna A
PURPOSE OF REVIEW/OBJECTIVE:Strongyloides stercoralis infection remains of concern due to its high associated morbidity among solid organ transplant recipients (SOTR) and the risk of donor-derived infection (DDI). We review key aspects of epidemiology to inform screening for and treatment of chronic infection among organ transplant candidates to reduce the risk of infectious complications in the posttransplant setting. RECENT FINDINGS/RESULTS:In this work, we offer guidance regarding the optimal management of Strongyloides hyperinfection syndrome and disseminated infection and offer recommendations regarding posttreatment surveillance and the potential need for repeat treatment during subsequent periods of augmented immunosuppression. This review also provides updated recommendations for screening of deceased and living donors as recently proposed by the Organ Procurement and Transplantation Network's Ad Hoc Disease Transmission Advisory Committee. SUMMARY/CONCLUSIONS:Risk reduction of Strongyloides infection in the SOTR population can be further enhanced by optimized treatment of infection, posttreatment surveillance during at-risk periods and recent proposed policy shifts to universal donor screening.
PMID: 39082077
ISSN: 1473-6527
CID: 5689732

Donor-derived strongyloidiasis: The beginning of the end?

Hogan, John I; Mehta, Sapna A; La Hoz, Ricardo M
PMID: 38874353
ISSN: 1399-3062
CID: 5669472

Reply to Yan

Hogan, John I; Duerr, Ralf; Heguy, Adriana
PMID: 36346103
ISSN: 1537-6591
CID: 5357182

Remdesivir resistance in transplant recipients with persistent COVID-19

Hogan, John I; Duerr, Ralf; Dimartino, Dacia; Marier, Christian; Hochman, Sarah E; Mehta, Sapna; Wang, Guiqing; Heguy, Adriana
New mutations conferring resistance to SARS-CoV-2 therapeutics have important clinical implications. We describe the first cases of an independently acquired V792I RNA-dependent RNA polymerase mutation developing in renal transplant recipients after remdesivir exposure. Our work underscores the need for augmented efforts to identify concerning mutations and address their clinical implications.
PMID: 36156117
ISSN: 1537-6591
CID: 5333962

Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection

Osinusi, Anu; Townsend, Kerry; Kohli, Anita; Nelson, Amy; Seamon, Cassie; Meissner, Eric G; Bon, Dimitra; Silk, Rachel; Gross, Chloe; Price, Angie; Sajadi, Mohammad; Sidharthan, Sreetha; Sims, Zayani; Herrmann, Eva; Hogan, John; Teferi, Gebeyehu; Talwani, Rohit; Proschan, Michael; Jenkins, Veronica; Kleiner, David E; Wood, Brad J; Subramanian, G Mani; Pang, Phillip S; McHutchison, John G; Polis, Michael A; Fauci, Anthony S; Masur, Henry; Kottilil, Shyam
IMPORTANCE/OBJECTIVE:There is an unmet need for interferon- and ribavirin-free treatment for chronic hepatitis C virus (HCV) infection in patients co-infected with human immunodeficiency virus (HIV). OBJECTIVE:To evaluate the rates of sustained virologic response (SVR) and adverse events in previously untreated patients with HCV genotype 1 and HIV co-infection following a 12-week treatment of the fixed-dose combination of ledipasvir and sofosbuvir. DESIGN, SETTING, AND PARTICIPANTS/METHODS:Open-label, single-center, phase 2b pilot study of previously untreated, noncirrhotic patients with HCV genotype 1 and HIV co-infection conducted at the Clinical Research Center of the National Institutes of Health, Bethesda, Maryland, from June 2013 to September 2014. Patients included those receiving antiretroviral therapy with HIV RNA values of 50 copies/mL or fewer and a CD4 T-lymphocyte count of 100 cells/mL or greater or patients with untreated HIV infection with a CD4 T-lymphocyte count of 500 cells/mL or greater. Serial measurements of safety parameters, virologic and host immune correlates, and adherence were performed. INTERVENTIONS/METHODS:Fifty patients with HCV genotype 1 never before treated for HCV were prescribed a fixed-dose combination of ledipasvir (90 mg) and sofosbuvir (400 mg) once daily for 12 weeks. MAIN OUTCOMES AND MEASURES/METHODS:The primary study outcome was the proportion of patients with sustained viral response (plasma HCV RNA level <12 IU/mL) 12 weeks after end of treatment. RESULTS:Forty-nine of 50 participants (98% [95% CI, 89% to 100%]) achieved SVR 12 weeks after end of treatment, whereas 1 patient experienced relapse at week 4 following treatment. In the patient with relapse, deep sequencing revealed a resistance associated mutation in the NS5A region conferring resistance to NS5A inhibitors, such as ledipasvir. The most common adverse events were nasal congestion (16% of patients) and myalgia (14%). There were no discontinuations or serious adverse events attributable to study drug. CONCLUSIONS AND RELEVANCE/CONCLUSIONS:In this open-label, uncontrolled, pilot study enrolling patients co-infected with HCV genotype 1 and HIV, administration of an oral combination of ledipasvir and sofosbuvir for 12 weeks was associated with high rates of SVR after treatment completion. Larger studies that also include patients with cirrhosis and lower CD4 T-cell counts are required to understand if the results of this study generalize to all patients co-infected with HCV and HIV. TRIAL REGISTRATION/BACKGROUND:clinicaltrials.gov Identifier:NCT01878799.
PMID: 25706232
ISSN: 1538-3598
CID: 5811572